|The following article is part of conference coverage from the 2018 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Montreal, Canada. Rheumatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts on bone health. Check back for the latest news from ASBMR 2018 .|
Intravenous (IV) ibandronate (IBN) treatment in patients with osteoporosis was effective in increasing lumbar spine bone mineral density (BMD) compared with patients treated with oral bisphosphonate (BP) therapy alone, according to a study presented at the American Society for Bone and Mineral Research 2018 Annual Meeting on October 1 in Montreal, Quebec, Canada.
Akinori Sakai, MD, and colleagues at the University of Occupational and Environmental Health in Kitakyushu, Japan, evaluated the effectiveness of IV IBN on BMD in patients with osteoporosis who had no increase in lumbar spine BMD despite oral BP therapy for 1 to 3 years.
Using data from the MOVEMENT Study, the researchers formed 2 treatment groups: 240 patients treated with monthly IV IBN, and 141 patients treated with oral BP. The primary end point for the study was the percent change in lumbar spine BMD from baseline to 12 months of IV IBN treatment.
Baseline characteristics for IV IBN vs oral BP were similar. Mean age was 74.8±7.6 vs 74.4±7.8 years; the majority of participants in both groups were women, 95.8% vs 97.2%; and the proportion of patients with prior fractures was 44.1% vs 52.5%, respectively.
Only 164 patients in the IV IBN group and 107 patients in the oral BP group completed the dual-energy x-ray absorptiometry assessment by the 1-year treatment period and positive change was observed in the interim tabulation of lumbar spine BMD in the IV IBN group.
“These results support the treatment as one of the new strategies that is expected to be beneficial for BMD as well as for treatment adherence,” according to study authors.
For more coverage of ASBMR 2018, click here.
Hagino H, Sakai A, Ikeda S, et al. Effectiveness of intravenous ibandronate on bone mineral density in patient with osteoporosis treated with oral bisphosphonate low responders – MOVEMENT Study. Presented at: 2018 American Society for Bone and Mineral Research Annual Meeting; September 28-October 1, 2018; Montreal, Quebec, Canada. Abstract 0959.
This article originally appeared on Endocrinology Advisor